Alliance Pharma Share Discussion Threads

[mazarin] 11/4/2013 11:23

If you do manage to attend MI I'd be interested to hear your findings and how well APH presents. From time to time John Dawson does video interviews and IMV comes across well.

[cisk] 10/4/2013 16:46

I don't think there's anything to worry about with the drop last week. The shares have had a good run lately so a bit of profit taking wouldn't be a surprise; the volume on Friday wasn't anything out of the ordinary.

Just view it as an opportunity to top up ;-)

Agree with your comments re: possible acquisitions (esp as they have agreed additional banking facilities recently); I don't think the Sanofi product will come back onstream until at least Q4 so will probably have no impact in the current financial year.

I'm hoping to attend the investor show in islington so will attempt to see John Dawson and ask him about the Sanofi product.

[cisk] 09/4/2013 03:34

Maz, probably a combination of profit taking ahead of the end of the tax year and also another batch of CULS conversion. Hope they never issue any more as these have been a drag on the share price each time they are converted.

Regards

Cisk

[mazarin] 08/4/2013 00:03

Clearly I spoke too soon, as the share price took a sudden dive (9 ticks down totalling 2p off) on Friday, that I can only assume was motivated by 'profit taking' after a good run in the absence of any News to the contrary? I find it very strange how just 24 hours earlier the share price was zooming northwards unabated and even momentarily touched 40p. Such rapid price movement is a little unusual for APH. Needless to say I wasn't tempted to sell and continue to hold awaiting developments.

[pimpernel4] 04/4/2013 10:54

Really getting a move on now...beautiful chart from July 2012 to April 2013. Should be some further interest off the back of the UK Investor Show in just over a week or so.

[pimpernel4] 04/4/2013 10:27

Well they are certainly coming out of the wood-work now.

Anyone else?

Good to have some action on here.

[norbert colon] 04/4/2013 10:22

I have been a holder since Jan 2011 and sitting on approx 30% profit so very happy holder and as usual wish i had a larger holding. Nigel Wray purchase seems to be catalyst but just happy to hold long term and enjoy the ride.

[mazarin] 04/4/2013 09:45

I agree essentially and that's one of the reasons why I hold APH, apart from it having a good senior management strategy. Thanks for your comments, incidentally since this discussion, I see its ticked up yet again to 39p. Perhaps we should keep talking, it must 'having an effect'.....eh I don't think so.

[dchristensen] 04/4/2013 09:25

It could just be investors having just topped up their ISAs for 12/13 and want a stock with a decently low P/E and high dividend yield.

[pimpernel4] 04/4/2013 09:18

Was going to comment myself the other day mazarin. Looks like we have a shot at consolidating in the 40s very soon indeed. Am equally awaiting some news. Let's see. Perhaps it is also simply a function of putting last year's hold ups behind the company. Onwards and upwards.

[mazarin] 04/4/2013 09:08

I can't believe I'm currently the only one here with an interest in APH and that the latest steady push north appears to continue without raising any additional comment. With yet another rise in early trading today, now just touching 38.5 this morning, suggests to me that there must be some positive news behind it, perhaps may be, another acquisition in the offing? Whatever's driving it, I'd expect the Company soon to make an announcement to account for recent rises in the share price (up 16.83% in last 4 weeks) since results were issued a few weeks ago. Does anyone else have a suggestion? Welcome as the ticks northwards are, it would be nice to understand what's giving it momentum.

[mazarin] 25/3/2013 08:53

Nice to see another good start today up a few ticks to 36p in early trading following last week that overall showed a 7.03% gain on the back of results. Looks like the APH's potential is getting some attention.

[mechanical trader] 21/3/2013 17:12

Alliance Pharma upgraded by Investec
21st March 2013, 15:00

Investec has upgraded its recommendation on speciality pharmaceutical company Alliance Pharma [LON:APH] to 'add' from 'hold' after the company reported its preliminary results which came in ahead of the brokers expectations.

The City broker raised its price target to 35.2 pence a share from 29.3 pence.

Earnings per share estimates have been increased by 16 per cent to 3.9 pence (from 3.35 pence) for 2013, by 16 per cent to 3.94 pence (from 3.39 pence) for 2014 and by 24 per cent to 4.56 pence (from 3.68 pence) for 2015.

Separately, Canaccord Genuity restated its 'hold' call on the stock (downgraded from 'buy' last week) and 34 pence price target in a research note to investors today.

The shares are up by more than 7 per cent in the past month and up nearly 13 per cent over the last three months.

At 2:55pm: Alliance Pharma share price was up 0.5 pence at 34.75 pence.

[mazarin] 21/3/2013 09:53

I too judge these to be good results and quite expect to see yet another tick up to 35p, even on this, an otherwise generally poor day amidst wider market jitters. I also reckon Analysts will soon be 'doing the math' and looking at these numbers with a more positive aspect that should also help matters longer term. I understand that Nigel Wray (big time holder of APH) will be one of a number of contributors to the forthcoming UKInvestor Show on 13th April. For details see:

[mechanical trader] 21/3/2013 07:51

Solid looking results.

Finncap were looking for EPS of 3p
this year 2012 and 3.6p year ending
2013 therefore company are 1 year ahead
on expected profits.

Dividend risen aswel 10%...excelent news.

[pimpernel4] 20/3/2013 14:43

Good to see the astute Mr Wray further increasing his substantial holding here.

[mazarin] 15/3/2013 19:20

In Feb I had an inckling the share price might start stirring and sure enough it did. Results are next Thursday and UK Investor Show presentation is due 13th April 2013. So things should be looking up.

[mechanical trader] 15/3/2013 09:25

APH Alliance Pharma. Results on the 21st of this month. Thursday. Think profits will beat broker forecast.. just added.

[mechanical trader] 13/2/2013 08:59

APH

Not far off breaking out.

BUY placed on it by SCSW tip sheet
this weekend.

Personaly Im looking for a bolt on
before results on 21st of March...

see historical item below.....

Alliance Pharma gets more ammo for acquisition drive
15th Jan 2013, 1:16 pm by Philip Whiterow

Alliance has £13.5mln to spend following the latest injection of funds. Alliance Pharma's (LON:APH) expansion of its acquisition fund is a key development for the specialist pharmaceutical company, according to broker Numis.

The group today announced an additional £10mln facility with Lloyds Banking Group, taking the total facility available to the group to make purchases up to £30mln.

Alliance has used £16.5mln of the facility and has £13.5mln to spend following the latest injection of funds.

Numis said that management has executed on 23 deals over the last 14 years and continually reiterates the strength of its M&A pipeline.

If the £13.5mln was fully deployed on acquisitions through 2013 at the historical average 3 times gross profit, the broker sees up to 30% upside to its 2014 profit forecasts.

"P/E multiples in the speciality pharma/generics peer group have expanded one point to 12x over the last couple of months - we therefore increase our price target to 42p, from 37p and reiterate our buy rating," said Numis.

Alliance also said profits will beat market forecasts for the year just ended after very strong sales of skin and eczema emollient Hydromol.

"As a result of a stronger than expected gross margin rate, pre-tax profits are expected to be slightly ahead of current market expectations," the specialist pharmaceutical group said.

Total revenues in 2012 will be £44.9mln, compared to £46mln in the previous year.

Sales were hit by Sanofi Pasteur's temporary suspension of the manufacture of Immucyst in June, but Hydromol's record performance offset some of the impact. Hydromol sales grew by 29% or £1.1 mln to £4.7 mln.

Last year's acquisitions, Opus Group and three anti-malarial brands, performed as expected, Alliance Pharma said.

Numis also raised its 2012 profit forecast to £10.5mln, from £10.2mln, following the update.

The company's business model is to acquire the rights to established niche pharmaceutical products. It now owns or licenses the rights to more than 60 products.

Shares rose by 4% to 33.5p.

[mazarin] 07/2/2013 14:40

Company proposes to have Analysts Briefing on results day at 10.00am Thursday 21 March 2013 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN on. I think we'll start to see movement here soon.

[montyhedge] 24/1/2013 07:49

Oh no, that means its going to fall then.

[lucky_punter] 18/1/2013 08:42

expansion of its acquisition fund is a key development for the specialist pharmaceutical company, according to broker Numis.